US · Healthcare · Biotechnology
EPS came in at -0.85 against a street estimate of -1.10 — a beat of 22.7%.
Analysts rate Dianthus Therapeutics Inc. a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $128.58.
| Fund | Stake |
|---|---|
| FMR Inc | 14.21% |
| Avidity Partners Management LP | 7.70% |
| BlackRock Inc | 5.81% |
| RA Capital Management, LLC | 4.78% |
| Wellington Management Company LLP | 4.75% |
| Fairmount Funds Management LLC | 4.64% |
| Vanguard Capital Management, LLC | 3.72% |
| Octagon Capital Advisors LP | 3.56% |
| Document | Date |
|---|---|
| Company announcement · Q2 2026 | 2026-06-12 |
| Shareholder vote results · Q2 2026 | 2026-05-22 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-09 |
| Company announcement · Q1 2026 | 2026-03-26 |
| Annual report FY2025 | 2026-03-09 |
| Quarterly report · Q3 2025 | 2025-11-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Dianthus Therapeutics Inc. — free to start.
Google PlayApp StoreData updated 2026-08-05.